ADMA vs AMRX
ADMA: ADMA manufactures and markets FDA-approved plasma-derived immune globulin products for immunodeficient and infectious disease patients, operating an integrated plasma collection and fractionation platform. AMRX: A diversified biopharmaceutical company providing a broad range of generic, branded, and specialty medicines alongside pharmaceutical distribution services.
Side-by-side fundamentals
| Metric | ADMA | AMRX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $8.46 | $18.32 | |
| Market cap as of 2026-08-03 | $2.0B | $5.8B | |
| P/E as of 2026-08-03 | 12.47 | 49.12 | ADMA lower |
| PEG as of 2026-08-03 | n/a | 2.85 | |
| Net margin as of 2026-08-03 | +32.4% | +4.0% | ADMA higher |
| Gross margin as of 2026-08-03 | +61.3% | +38.7% | ADMA higher |
| Operating margin as of 2026-08-03 | +41.5% | +14.3% | ADMA higher |
| ROE as of 2026-08-03 | +39.0% | -34.9% | ADMA higher |
| ROA as of 2026-08-03 | +27.4% | +3.4% | ADMA higher |
| Debt / equity as of 2026-08-03 | 0.50 | 136.58 | ADMA lower |
| Revenue growth (YoY) as of 2026-08-03 | +11.0% | +7.6% | ADMA higher |
| Revenue CAGR (3y) SEC XBRL | +49.0% | +10.9% | ADMA higher |
| Beta as of 2026-08-03 | 1.16 | 0.88 | |
| 1-year return as of 2026-07-31 close | -54.8% | +134.3% | AMRX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.